Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.

Date publication

janvier 2017

Journal

Annals of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François

Tous les auteurs :
Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28469364

Résumé

The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chronic hepatitis C (CHC) in routine clinical practice.

Référence

Ann Gastroenterol. 2017 ;30(3):327-343